NewLink Genetics

NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. The Company's biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. NewLink's small-molecule product candidates are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas.

Company Growth (employees)
Type
Public
HQ
Ames, US
Founded
1999
Size (employees)
122 (est)
NewLink Genetics was founded in 1999 and is headquartered in Ames, US

NewLink Genetics Office Locations

NewLink Genetics has offices in Ames, Austin and Devens
Ames, US (HQ)
5100 2503 S Loop Dr
Devens, US
108 94 Jackson Rd
Austin, US
100 2700 Vía Fortuna

NewLink Genetics Financials and Metrics

NewLink Genetics Financials

NewLink Genetics's revenue was reported to be $35.8 m in FY, 2016
USD

Revenue (Q2, 2017)

10.4 m

Net income (Q2, 2017)

(16.7 m)

EBIT (Q2, 2017)

(16.7 m)

Market capitalization (13-Nov-2017)

266.5 m

Cash (30-Jun-2017)

107.8 m
NewLink Genetics's current market capitalization is $266.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.1 m172.6 m68.5 m35.8 m

Revenue growth, %

15691%(60%)(48%)

R&D expense

93.3 m

General and administrative expense

33.2 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

39.2 m7.4 m14.2 m5.7 m2 m15.3 m2.8 m10.4 m

R&D expense

6.1 m6.4 m6.5 m10.9 m18 m16.1 m22.5 m21.9 m27.4 m24.5 m15.7 m18.2 m

General and administrative expense

2.3 m3.3 m2.9 m4.9 m8.4 m7.3 m7.4 m9.2 m9.1 m7.7 m8.2 m8.9 m

Operating expense total

8.4 m9.6 m9.3 m15.8 m26.3 m23.4 m29.9 m31.1 m36.5 m32.2 m24 m27.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

61.3 m190.4 m195.6 m131.5 m

Accounts Receivable

1.3 m3.7 m5.4 m24.5 m

Inventories

5 m5.9 m

Current Assets

64 m230.5 m208.1 m167.9 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

52 m83.7 m76.9 m51.1 m206.6 m203.4 m197.1 m177 m160.5 m148.3 m118.2 m107.8 m

Accounts Receivable

1.2 m251 k161 k2.7 m11 m12.6 m14.5 m6.7 m3.2 m15 m11.3 m

Current Assets

54.1 m85.3 m78.2 m78.8 m251.1 m234.5 m217.2 m189.4 m172 m179.2 m143.2 m130.2 m

PP&E

7.4 m7.2 m6.5 m5.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(31.2 m)102.9 m(40.4 m)(85.2 m)

Depreciation and Amortization

891 k1.1 m1.6 m2.1 m

Accounts Receivable

1.1 m(2.4 m)(1.7 m)(19.1 m)

Inventories

3.4 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(8.1 m)(9.2 m)(9.2 m)(5.6 m)11.2 m(14.1 m)(15.9 m)(23.7 m)(32.4 m)(15.5 m)(20.9 m)

Accounts Receivable

161 k2.7 m11 m12.6 m14.5 m6.7 m3.2 m15 m

Accounts Payable

687 k2.9 m4.1 m1.5 m1.5 m3 m1.8 m2.4 m9.6 m
USDY, 2017

Revenue/Employee

85 k

Financial Leverage

1.3 x
Show all financial metrics

NewLink Genetics Market Value History

NewLink Genetics's Web-traffic and Trends

NewLink Genetics Company Life and Culture

You may also be interested in